I-Mab (IMAB) Stock Forecast & Price Target

$1.36

-0.03 (-2.16%)

(As of 07/26/2024 ET)

I-Mab - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 4 Analyst Ratings

Based on 4 Wall Street analysts who have issued ratings for I-Mab in the last 12 months, the stock has a consensus rating of "Buy." Out of the 4 analysts, 4 have given a buy rating for IMAB.

Consensus Price Target

$12.25
800.74% Upside

High Forecast	$25.00
Average Forecast	$12.25
Low Forecast	$6.00

According to the 4 analysts' twelve-month price targets for I-Mab, the average price target is $12.25. The highest price target for IMAB is $25.00, while the lowest price target for IMAB is $6.00. The average price target represents a forecasted upside of 800.74% from the current price of $1.36.

Type	Current Forecast 7/27/23 to 7/26/24	1 Month Ago 6/27/23 to 6/26/24	3 Months Ago 4/28/23 to 4/27/24	1 Year Ago 7/27/22 to 7/27/23
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$12.25	$12.25	$12.25	$24.67
Forecasted Upside	800.74% Upside	569.92% Upside	569.92% Upside	617.05% Upside

Get I-Mab Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter.

Ad Unstoppable Prosperity

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

IMAB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IMAB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

I-Mab Stock vs. The Competition

Type	I-Mab	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.72	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	800.74% Upside	3,123.18% Upside	9.15% Upside
News Sentiment Rating	Very Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/12/2024	Needham & Company LLC 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$6.00	+231.49%
3/18/2024	HC Wainwright 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $8.00	+339.56%
3/18/2024	Piper Sandler 2 of 5 stars		Lower Target	Overweight ➝ Overweight	$15.00 ➝ $10.00	+449.45%
1/12/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:29 PM ET.

IMAB Forecast - Frequently Asked Questions

What is I-Mab's forecast for 2024?: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for I-Mab is $12.25, with a high forecast of $25.00 and a low forecast of $6.00.
Should I buy or sell I-Mab stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMAB shares.
Does I-Mab's stock price have much upside?: According to analysts, I-Mab's stock has a predicted upside of 569.92% based on their 12-month stock forecasts.
Do Wall Street analysts like I-Mab more than its competitors?: Analysts like I-Mab more than other "medical" companies. The consensus rating for I-Mab is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IMAB compares to other companies.